The efficacy of BMP-2 to induce bone ingrowth in a total hip replacement model.
The purpose of this canine total hip arthroplasty (THA) study was fourfold: (1) to quantify the efficacy of rhBMP-2 in a carrier (alphaBSM) versus alphaBSM alone, and versus untreated controls to induce bone formation across a defect between a porous acetabular component and host bone; (2) to quantify whether rhBMP-2/alphaBSM improves bone growth into the porous surface beneath that defect; (3) to quantify the efficacy of rhBMP-2/alphaBSM in inducing bone ingrowth into the porous layer at points of intimate bone-implant contact; and (4) to determine whether rhBMP-2/alphaBSM placed in the lateral uncovered aspect of the porous acetabular component promotes de novo bone formation. Fifteen dogs were sacrificed 12 weeks after uncemented THA. Five dogs received rhBMP-2/alphaBSM, five dogs received alphaBSM, and five dogs were controls. In contrast to the controls in which no bone filled the defect, the rhBMP-2/alphaBSM induced defect filling and full bone formation in the underlying porous coating. The alphaBSM produced an intermediary response. However, no increase in new bone formation occurred at sites of intimate bone porous surface contact. Recombinant bone morphogenetic protein-2/alphaBSM promoted defect filling and bone ingrowth into the porous coating beneath the defect region, both of potential value in future total joint replacement surgery.
Bragdon
Charles R
CR
Orthopaedic Biomechanics and Biomaterials Laboratory, Adult Reconstructive Unit, Department of Orthopaedic Surgery, Massachusetts General Hospital, Jackson Bldg. 1205, 55 Fruit Street, Boston, MA 02114, USA. cbragdon@partners.org
Doherty
Arin M
AM
Rubash
Harry E
HE
Jasty
Murali
M
Li
X Jian
XJ
Seeherman
Howard
H
Harris
William H
WH
D000818:Animals; D019644:Arthroplasty, Replacement, Hip; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D018786:Bone Substitutes / Q000494:pharmacology*; D002130:Calcium Phosphates / Q000494:pharmacology; D004285:Dogs; D004337:Drug Carriers; D006622:Hip Prosthesis; D023421:Models, Animal; D016348:Osseointegration / Q000187:drug effects*; D011474:Prosthesis Design; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D002130:Calcium Phosphates; D004337:Drug Carriers; D016212:Transforming Growth Factor beta